Immunogenicity and protective efficacy of mycobacterial DNA vaccines incorporating plasmid-encoded cytokines against Mycobacterium bovis

Immunology and Cell Biology

Volumn 88, Issue 6, 2010, Pages 651-657

  Young, Sarah L ^a   Slobbe, Lynn J ^a   Peacey, Matthew ^a   Gilbert, Sarah C ^b   Buddle, Bryce M ^c   De Lisle, Geoffrey W ^d   Buchan, Glenn S ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c AGRESEARCH GRASSLANDS   (New Zealand)

^d AGRESEARCH   (New Zealand)

Author keywords

DNA vaccines; MVA vaccine; Mycobacterium bovis; prime boost; tuberculosis

Indexed keywords

BACTERIAL VACCINE; BCG VACCINE; DNA VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; INTERLEUKIN 7; MODIFIED VACCINIA VIRUS ANKARA VACCINE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1ALPHA; MYCOBACTERIUM ANTIGEN; MYCOBACTERIUM BOVIS ANTIGEN 85A; UNCLASSIFIED DRUG; VACCINIA VACCINE;

ACTIVE IMMUNIZATION; AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL VIRULENCE; BCG VACCINATION; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; COLONY FORMING UNIT; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG EFFICACY; IMMUNOGENICITY; LUNG INFECTION; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM BOVIS; NONHUMAN; PLASMID; PROTECTION;

ACYLTRANSFERASES; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINE CCL3; EPITOPES, T-LYMPHOCYTE; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; INTERLEUKIN-7; MICE; MICE, INBRED BALB C; MYCOBACTERIUM BOVIS; PLASMIDS; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY; VACCINES, DNA; VIRAL VACCINES;

MURINAE; MUS; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS;

EID: 77955661783     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2010.25     Document Type: Article

References (35)

1. Raviglione MC, Snider DE, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 1995; 273: 220-226.
2. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. W.H.O. Global Surveillance and Monitoring Project. JAMA 1999; 282: 677-686.
3. Steele JH. Regional and country status report. In: Thoen CO, Steele JH (eds). Mycobacterium Bovis Infection in Animals and Humans. Ames Iowa Press, 1995. pp 169-172.
4. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg H et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994; 271: 698-702.
5. Fine PEM. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 346: 1339-1345.
6. Martin E, Kamath AT, Briscoe H, Britton WJ. The combination of plasmid interleukin-12 with a single DNA vaccine is more effective than Mycobacterium bovis (bacille Calmette-Guèrin) in protecting against systemic Mycobacterim avium infection. Immunology 2003; 109: 308-314.
7. Tanghe A, DSouza S, Rosseels V, Denis O, Ottenhoff TH, Dalemans W et al. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect Immun 2001; 69: 3041-3047.
8. Wang QM, Sun SH, Hu ZL, Yin M, Xiao CJ, Zhang JC. Improved immunogenicity of a tuberculosis DNA vaccine encoding ESAT by DNA priming and protein boosting. Vaccine 2004; 22: 3622-3627.
9. Gilbert SC, Moorthy VS, Andrews L, Pathan AA, McConkey SJ, Vuola JM et al. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 2006; 24: 4554-4561.
10. Liu S, Gong Q, Wang C, Liu H, Wang Y, Guo S et al. A novel DNA vaccine for protective immunity against virulent Mycobacterium bovis in mice. Immunol Lett 2008; 117: 136-145.
11. Teixeira FM, Teixeira HC, Ferreira AP, Rodrigues MF, Azevedo V, Macedo GC et al. DNA vaccine using Mycobacterium bovis Ag85B antigen induces partial protection against experimental infection in BALB/c mice. Clin Vacc Immunol 2006; 13: 930-935.
12. Triccas JA, Sun L, Palendira U, Britton WJ. Comparative affects of plasmid-encoded interleukin and interleukin on the protective efficacy of DNA vaccination against Mycobacterium tuberculosis. Immunol Cell Biol 2002; 80: 346-350.
13. Uchijima M, Nagata T, Koide Y. Chemokine receptor-mediated delivery of mycobacterial MPT protein efficiently induces antigen-specific T-cell responses. Vaccine 2008; 26: 5165-5169.
14. Umemura M, Nishimura H, Saito K, Yajima T, Matsuzaki G, Mizuno S et al. Interleukin- as an immune adjuvant to increase the efficacy of Mycobacterium bovis bacillus Calmette-Gué rin vaccination. Infect Immun 2003; 71: 6045-6048.
15. Melchionda F, Fry TJ, Milliron MJ, McKirdy MA, Tagaya Y, Mackall CL. Adjuvant IL- or IL- overcomes immunodominance and improves survival of the CD8+ memory cell pool. J Clin Invest 2005; 115: 1177-1187.
16. Ruberti M, De Melo LK, Dos Santos SA, Brandao IT, Soares EG, Silva CL et al. Primeboost vaccination based on DNA and protein-loaded microspheres for tuberculosis prevention. J Drug Target 2004; 12: 195-203.
17. Cai H, Yu DH, Hu XD, Li SX, Zhu YX. A combined DNA vaccine-prime, BCG-boost strategy results in better protection against Mycobacterium bovis challenge. DNA Cell Biol 2006; 25: 438-447.
18. Williams A, Davies A, Marsh PD, Chambers MA, Hewinson RG. Comparison of the protective efficacy of bacille Calmette-Gué rin vaccination against aerosol challenge with Mycobacterium tuberculosis and Mycobacterium bovis. Clin Infect Dis 2000; 30(Suppl 3): S299-S301.
19. Taylor JL, Turner OC, Basaraba RJ, Belisle JT, Huygen K, Orme IM. Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect Immun 2003; 71: 2192-2198.
20. Skinner MA, Ramsay AJ, Buchan GS, Keen DL, Ranasinghe C, Slobbe L et al. A DNA prime-live vaccine boost strategy in mice can augment IFN-gamma responses to mycobacterial antigens but does not increase the protective efficacy of two attenuated strains of Mycobacterium bovis against bovine tuberculosis. Immunology 2003; 108: 548-555.
21. Kirman JR, Turon T, Su H, Li A, Kraus C, Polo JM et al. Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A. Infect Immun 2003; 71: 575-579.
22. Britton WJ, Palendira U. Improving vaccines against tuberculosis. Immunol Cell Biol 2003; 81: 34-45.
23. Jeyanathan M, Mu J, Kugathasan K, Zhang X, Damjanovic D, Small C et al. Airway delivery of soluble mycobacterial antigens restores protective mucosal immunity by single intramuscular plasmid DNA tuberculosis vaccination: role of proinflammatory signals in the lung. J Immunol 2008; 181: 5618-5626.
24. Feske M, Nudelman RJ, Medina M, Lew J, Singh M, Couturier J et al. Enhancement of human antigen-specific memory T-cell responses by interleukin-7 may improve accuracy in diagnosing tuberculosis. Clin Vaccine Immunol 2008; 15: 1616-1622.
25. Mittrücker HW, Steinhoff U, Kohler A, Krause M, Lazar D, Mex P. Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis. Proc Natl Acad Sci USA 2007; 104: 12434-12439.
26. Forbes EK, Sander C, Ronan EO, McShane H, Hill AV, Beverley PC et al. Multifunctional, high-level cytokine-producing Th cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 2008; 181: 4955-4964.
27. Chambers MA, Stagg D, Gavier-Widén D, Lowrie D, Newell D, Hewinson RG. A DNA vaccine encoding MPB from Mycobacterium bovis reduces M.bovis dissemination to the kidneys of mice and is expressed in primary cell cultures of the European badger (Meles meles). Res Vet Sci 2001; 71: 119-126.
28. McShane H, Pathan AA, Sander CR, Goonetilleke NP, Fletcher HA, Hill AV. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis 2005; 85: 47-52.
29. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCGprimed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004; 10: 1240-1244.
30. McShane H, Behboudi S, Goonetilleke N, Brookes R, Hill AV. Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(+)- and CD4(+)-T-cell epitopes from antigen 85A. Infect Immun 2002; 70: 1623-1626.
31. Chakrabarti S, Brechling K, Moss B. Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol 1985; 5: 3403-3409.
32. McShane H, Brookes R, Gilbert SC, Hill AV. Enhanced immunogenicity of CD4(+) T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 2001; 69: 681-686.
33. Aldwell FE, Tucker IG, de Lisle GW, Buddle BM. Oral delivery of Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculosis in mice. Infect Immun 2003; 71: 101-108.
34. DSouza S, Rosseels V, Denis O, Tanghe A, De Smet N, Jurion F et al. Improved tuberculosis DNA vaccines by formulation in cationic lipids. Infect Immun 2002; 70: 3681-3688.
35. Brandt L, Oettinger T, Holm A, Andersen AB, Andersen P. Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis. J Immunol 1996; 157: 3527-3533.